One Lambda | GenomeWeb

One Lambda

NEW YORK (GenomeWeb) – Diaxonhit today announced that its affiliate InGen has renewed an exclusive deal to distribute One Lambda's transplantation diagnostic tests in France.
Financial and other details of the partnership were not disclosed.

Title: System and method for nucleic acids sequencing by phased synthesis.
Patent Number: 8,747,751
Filed: June 10, 2009

NEW YORK (GenomeWeb News) – Regulators in the US and Canada have cleared One Lambda's companion software to molecular typing and antibody screening products, the Thermo Fisher Scientific business said late Wednesday.

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has executed a Covenant Not to Sue and Release agreement with transplant diagnostics firm One Lambda.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its acquisition of transplant diagnostics firm One Lambda for $925 million.

Cepheid last week filed suit against Roche seeking to invalidate a pair of PCR patents owned by Roche.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has priced its $1.3 billion offering of senior notes, the firm announced after the close of the market yesterday.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it intends to offer senior notes to cover the cost of its $925 million acquisition of One Lambda.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today announced it intends to buy transplant diagnostics firm One Lambda for $925 million in cash.

The firms began their partnership, which is aimed at human leukocyte antigen typing and antibody screening for the organ transplantation market, in 2000.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.